Human protein tyrosine phosphatase inhibitors and methods of use

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO RE46592
SERIAL NO

14938526

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present disclosure relates to compounds effective as human protein tyrosine phosphatase beta (HPTP-β) inhibitors thereby regulating angiogenesis. The present disclosure further relates to compositions comprising said human protein tyrosine phosphatase beta (HPTP-β) inhibitors, and to methods for regulating angiogenesis.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
EYEPOINT PHARMACEUTICALS INC480 PLEASANT STREET SUITE A-210 WATERTOWN MA 02472

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Amarasinghe, Kande K D Ellicott City, US 16 643
Clark, Cynthia Monesa Concord, US 21 895
Gray, Jeffrey Lyle Loveland, US 33 1158
Maier, Matthew B Springboro, US 21 895
Nichols, Ryan Matthew Cincinnati, US 22 908

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Apr 30, 2025
11.5 Year Payment $7400.00 $3700.00 $1850.00 Apr 30, 2029
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00